Science Explorer Back to mapMap
Discussion
Institution · Pasqual Maragall Foundation

Most cited papers from Pasqual Maragall Foundation

Pasqual Maragall Foundation

What are the most cited papers from Pasqual Maragall Foundation?

The most cited paper from Pasqual Maragall Foundation is "NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease" (Clifford R. Jack et al., 2018), with 10,885 citations. Next come "Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria" (3,373) and "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria" (1,953).

Showing 50 of 60 papers. Every paper with more than 179 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease Clifford R. Jack et al. · Alzheimer s & Dementia Open access Apr 2018 10,885
2 Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria Bruno Dubois et al. · The Lancet Neurology Open access 18 May 2014 3,373
3 Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria Bruno Dubois et al. · Alzheimer s & Dementia Open access Mar 2016 1,953
4 The characterisation of subjective cognitive decline Frank Jessen, Rebecca England Amariglio, Rachel F. Buckley et al. · The Lancet Neurology Open access 17 Jan 2020 1,435
5 Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic Harald Juergen Hampel, Sid E. O’Bryant, José Luís Molinuevo et al. · Nature Reviews Neurology ReviewOpen access 8 Oct 2018 727
6 Alzheimer’s disease prevention: from risk factors to early intervention Marta Crous‐Bou, Carolina Minguillón, Nina Gramunt et al. · Alzheimer s Research & Therapy Open access 12 Sep 2017 702
7 Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum Andréa Lessa Benedet et al. · JAMA Neurology Open access 20 Oct 2021 668
8 Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors Nicole M. Warrington et al. · Nature Genetics Open access208 authors May 2019 664
9 Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers Giovanni Battista Frisoni et al. · The Lancet Neurology Open access 11 Jul 2017 646
10 Implementation of subjective cognitive decline criteria in research studies José Luís Molinuevo, Laura A. Rabin, Rebecca England Amariglio et al. · Alzheimer s & Dementia Open access 5 Nov 2016 600
11 Dementia care during COVID-19 Huali Wang, Tao Li, Paola Barbarino et al. · The Lancet Open access 30 Mar 2020 594
12 World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia Miia Kivipelto et al. · Alzheimer s & Dementia Open access Jul 2020 552
13 sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers Marc Suárez‐Calvet et al. · EMBO Molecular Medicine Open access 3 Mar 2016 545
14 Current state of Alzheimer’s fluid biomarkers José Luís Molinuevo, Scott Ayton, Richard Batrla et al. · Acta Neuropathologica Open access 28 Nov 2018 533
15 Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia Rosalinde E.R. Slot et al. · Alzheimer s & Dementia Open access 13 Dec 2018 464
16 Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected Marc Suárez‐Calvet et al. · EMBO Molecular Medicine Open access 10 Nov 2020 424
17 Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology for the Alzheimer’s Disease Neuroimaging Initiative et al. · Molecular Neurodegeneration Open access 10 Jan 2019 387
18 Long-term exposure to residential green and blue spaces and anxiety and depression in adults: A cross-sectional study Mireia Gascón, Gonzalo Sánchez‐Benavides, Payam Dadvand et al. · Environmental Research 18 Jan 2018 387
19 CSF biomarker variability in the Alzheimer's Association quality control program Niklas Mattsson et al. · Alzheimer s & Dementia Open access145 authors May 2013 386
20 Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline Juan Lantero‐Rodriguez, Thomas K. Karikari, Marc Suárez‐Calvet et al. · Acta Neuropathologica Open access 27 Jul 2020 380
21 Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative Thomas K. Karikari, Andréa Lessa Benedet, Nicholas James Ashton et al. · Molecular Psychiatry 26 Oct 2020 378
22 Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease Marta Milà‐Alomà et al. · Nature Medicine Open access 11 Aug 2022 370
23 APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease Juan Fortea, Jordi Pegueroles, Daniel Andres Alcolea et al. · Nature Medicine Open access May 2024 362
24 Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility Thomas K. Karikari, Nicholas James Ashton, Gunnar Brinkmalm et al. · Nature Reviews Neurology ReviewOpen access 18 May 2022 353
25 Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores Itziar de Rojas et al. · Nature Communications Open access572 authors 7 Jun 2021 350
26 Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease Michael Ewers, Nicolai Franzmeier, Marc Suárez‐Calvet et al. · Science Translational Medicine Open access 28 Aug 2019 348
27 Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease Alexis Moscoso et al. · JAMA Neurology Open access 14 Jan 2021 335
28 GA4GH: International policies and standards for data sharing across genomic research and healthcare Heidi L. Rehm et al. · Cell Genomics Open access202 authors Nov 2021 325
29 Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry Piotr Lewczuk et al. · The World Journal of Biological Psychiatry Open access 27 Oct 2017 321
30 The Corticocortical Structural Connectivity of the Human Insula Jimmy Ghaziri, Alan Tucholka, Gabriel Girard et al. · Cerebral Cortex 18 Dec 2015 320
31 Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease Suzanne Elizabeth Schindler et al. · Nature Reviews Neurology ReviewOpen access 12 Jun 2024 296
32 The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk Yuetiva K. Deming et al. · Science Translational Medicine Open access 14 Aug 2019 288
33 Evolutionary constraint and innovation across hundreds of placental mammals Matthew J. Christmas et al. · Science Open access179 authors 27 Apr 2023 279
34 Cerebrospinal Fluid Aβ 42/40 Corresponds Better than Aβ 42 to Amyloid PET in Alzheimer’s Disease Piotr Lewczuk, Anja Matzen, Kaj Blennow et al. · Journal of Alzheimer s Disease Open access 14 Oct 2016 270
35 Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum Marta Milà‐Alomà, Gemma Salvadó, Juan Domingo Gispert et al. · Alzheimer s & Dementia Open access 23 Jun 2020 267
36 Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study Flora Hillegonde Duits et al. · Alzheimer s & Dementia Open access 11 Sep 2015 262
37 Dynamic functional connectivity reveals altered variability in functional connectivity among patients with major depressive disorder Murat Demirtaş, Cristian Tornador, Carles Falcón et al. · Human Brain Mapping Open access 28 Apr 2016 247
38 Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies William Stephen Harris et al. · Nature Communications Open access 22 Apr 2021 245
39 Effect of long-term exposure to air pollution on anxiety and depression in adults: A cross-sectional study Cristina Vert, Gonzalo Sánchez‐Benavides, David R. Martinez et al. · International Journal of Hygiene and Environmental Health 3 Jul 2017 244
40 Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum Alexis Moscoso, Michel J. Grothe, Nicholas James Ashton et al. · Brain Open access 26 Oct 2020 242
41 Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays Nicholas James Ashton et al. · Alzheimer s & Dementia Open access 12 Nov 2022 239
42 The roles of inflammation and immune mechanisms in Alzheimer's disease Linda J. Van Eldik, María C. Carrillo, Patricia E. Cole et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions Open access 30 May 2016 239
43 Novel loci for childhood body mass index and shared heritability with adult cardiometabolic traits Suzanne Vogelezang et al. · PLoS Genetics Open access145 authors 12 Oct 2020 237
44 Quantification of amyloid PET for future clinical use: a state-of-the-art review Hugh Pemberton, Lyduine Eisa Collij, Fiona Heeman et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access 7 Apr 2022 230
45 Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics Betty Marije Tijms et al. · Brain Open access 9 Sep 2020 227
46 Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders Youssef Hanna El-Hayek, Ryan E. Wiley, Charles P. Khoury et al. · Journal of Alzheimer s Disease Open access 25 Jun 2019 225
47 A global catalog of whole-genome diversity from 233 primate species Lukas F. K. Kuderna et al. · Science Open access Jun 2023 220
48 Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers for the Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study, Gemma Salvadó, José Luís Molinuevo et al. · Alzheimer s Research & Therapy Open access 21 Mar 2019 215
49 Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project Craig Ritchie, José Luís Molinuevo, Luc Truyen et al. · The Lancet Psychiatry 15 Dec 2015 213
50 An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders Nicholas James Ashton, Abdul Hye, Anto Praveen Rajkumar et al. · Nature Reviews Neurology ReviewOpen access 22 Apr 2020 201

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.